MA31067B1 - Composés et procédés permettant d'inhiber l'interaction des protéines bcl avec des partenaires de liaison. - Google Patents
Composés et procédés permettant d'inhiber l'interaction des protéines bcl avec des partenaires de liaison.Info
- Publication number
- MA31067B1 MA31067B1 MA31972A MA31972A MA31067B1 MA 31067 B1 MA31067 B1 MA 31067B1 MA 31972 A MA31972 A MA 31972A MA 31972 A MA31972 A MA 31972A MA 31067 B1 MA31067 B1 MA 31067B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- methods
- binding partners
- bcl proteins
- inhibiting interaction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un aspect de la présente invention concerne des composés hétérocycliques qui lient les protéines bcl et inhibent la fonction bci. Un autre aspect de la présente invention concerne des compositions comprenant un composé hétérocyclique selon l'invention. La présente invention concerne des procédés de traitement et de modulation des troubles associés à l'hyperprolifération, tels que le cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/600,332 US7842815B2 (en) | 2004-06-17 | 2006-11-15 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
PCT/US2007/023941 WO2008060569A1 (fr) | 2006-11-15 | 2007-11-14 | Composés et procédés permettant d'inhiber l'interaction des protéines bcl avec des partenaires de liaison |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31067B1 true MA31067B1 (fr) | 2010-01-04 |
Family
ID=39064388
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31972A MA31067B1 (fr) | 2006-11-15 | 2009-06-10 | Composés et procédés permettant d'inhiber l'interaction des protéines bcl avec des partenaires de liaison. |
Country Status (21)
Country | Link |
---|---|
US (2) | US7842815B2 (fr) |
EP (1) | EP2094673B1 (fr) |
JP (2) | JP2010510214A (fr) |
KR (1) | KR101530721B1 (fr) |
CN (1) | CN101583606B (fr) |
AU (1) | AU2007319848B2 (fr) |
BR (1) | BRPI0718606A2 (fr) |
CA (1) | CA2669596C (fr) |
EC (1) | ECSP099398A (fr) |
ES (1) | ES2537762T3 (fr) |
GT (1) | GT200900123A (fr) |
HK (1) | HK1130057A1 (fr) |
IL (1) | IL198597A (fr) |
MA (1) | MA31067B1 (fr) |
MX (1) | MX2009005184A (fr) |
MY (1) | MY156754A (fr) |
NO (1) | NO20092306L (fr) |
NZ (1) | NZ577243A (fr) |
RU (1) | RU2449996C2 (fr) |
TN (1) | TN2009000182A1 (fr) |
WO (1) | WO2008060569A1 (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2118123T3 (en) | 2007-01-31 | 2016-01-25 | Dana Farber Cancer Inst Inc | Stabilized p53 peptides and uses thereof |
ES2610531T3 (es) | 2007-03-28 | 2017-04-28 | President And Fellows Of Harvard College | Polipéptidos cosidos |
US20090275519A1 (en) * | 2008-02-08 | 2009-11-05 | Aileron Therapeutics, Inc. | Therapeutic peptidomimetic macrocycles |
US8314250B2 (en) * | 2009-11-24 | 2012-11-20 | Hoffmann-La Roche Inc. | Sultam derivatives |
RU2639523C2 (ru) | 2011-10-18 | 2017-12-21 | Эйлерон Терапьютикс, Инк. | Пептидомиметические макроциклы и их применение |
EP3367096B1 (fr) | 2012-02-06 | 2019-11-27 | DiscoveRx Corporation | Détection d'événements de liaison intracellulaire par mesure d'abondance de protéines |
MX362492B (es) | 2012-02-15 | 2019-01-21 | Aileron Therapeutics Inc | Macrociclos peptidomiméticos. |
JP6450192B2 (ja) | 2012-02-15 | 2019-01-09 | エイルロン セラピューティクス,インコーポレイテッド | トリアゾール架橋した、およびチオエーテル架橋したペプチドミメティック大環状化合物 |
CN103656642A (zh) * | 2012-08-31 | 2014-03-26 | 中国科学院上海生命科学研究院 | 预防和治疗结直肠癌的方法和试剂 |
US20160068463A1 (en) | 2012-11-14 | 2016-03-10 | Metabolix, Inc. | Production of salts of 4-hydroxybutyrate using biobased raw materials |
WO2014138429A2 (fr) | 2013-03-06 | 2014-09-12 | Aileron Therapeutics, Inc. | Macrocycles peptidomimétiques et leur utilisation dans la régulation de hif1alpha |
US9993472B2 (en) | 2014-01-28 | 2018-06-12 | Unity Biotechnology, Inc. | Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2 |
WO2015160975A2 (fr) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Polythérapies |
KR20170058424A (ko) | 2014-09-24 | 2017-05-26 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방 거대고리 및 이의 용도 |
EP3294318A4 (fr) | 2015-03-20 | 2019-04-03 | Aileron Therapeutics, Inc. | Macrocycles peptidomimétiques et leurs utilisations |
JP2018528217A (ja) | 2015-09-10 | 2018-09-27 | エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. | Mcl−1のモジュレーターとしてのペプチド模倣大環状分子 |
MX2018011666A (es) | 2016-03-28 | 2019-07-08 | Presage Biosciences Inc | Combinaciones farmaceuticas para el tratamiento de cancer. |
WO2017197036A1 (fr) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Dégronimères spirocycliques pour la dégradation de protéines cibles |
CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
WO2020132561A1 (fr) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Dégradation ciblée de protéines |
WO2021233948A1 (fr) | 2020-05-19 | 2021-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédé de traitement d'une infection pulmonaire par un pathogène |
WO2022008464A1 (fr) | 2020-07-06 | 2022-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinaison d'antibiotiques anti néoplasiques et d'inhibiteurs de bcl-2 pour le traitement de la leucémie myéloïde aiguë (lma) entraînée par npm-1 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
JPS55133364A (en) | 1979-04-03 | 1980-10-17 | Mitsubishi Petrochem Co Ltd | Preparation of isoxazolidine derivative |
DE3643012A1 (de) | 1986-12-17 | 1988-06-30 | Hoechst Ag | 2,3-disubstituierte isoxazolidine, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
DK0527736T3 (da) | 1990-05-18 | 1997-10-20 | Hoechst Ag | Isoxazol-4-carboxylsyreamider og hydroxyalkyliden-cyanoacetamider, lægemidler indeholdende disse forbindelser og anvendelsen af disse lægemidler. |
US5294617A (en) * | 1993-04-23 | 1994-03-15 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
ES2134870T3 (es) * | 1993-05-01 | 1999-10-16 | Merck Patent Gmbh | Antagonistas del receptor de adhesion. |
ES2154326T3 (es) | 1993-11-24 | 2001-04-01 | Du Pont Pharm Co | Antagonistas de receptor de fibrinogeno de isoxazolina e isoxazol. |
DK0749428T3 (da) | 1994-03-09 | 1998-11-16 | Pfizer | Isooxazolinforbindelser som inhibitorer af TNF-frigivelse |
US5514505A (en) * | 1995-05-15 | 1996-05-07 | Xerox Corporation | Method for obtaining improved image contrast in migration imaging members |
DE19539638A1 (de) | 1995-10-25 | 1997-04-30 | Hoechst Ag | Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen |
US6221865B1 (en) * | 1995-11-06 | 2001-04-24 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
CA2262117A1 (fr) | 1996-08-16 | 1998-02-19 | The Dupont Merck Pharmaceutical Company | Amidinophenyl-pyrrolidines, -pyrrolines et -isoxazolidines et leurs derives |
AU5239198A (en) | 1996-10-16 | 1998-05-11 | President And Fellows Of Harvard College, The | Droplet assay system |
ES2387211T3 (es) | 1997-05-07 | 2012-09-18 | University Of Pittsburgh | Inhibidores de proteínas isoprenil transferass |
WO2001016115A1 (fr) | 1999-09-01 | 2001-03-08 | Chemrx Advanced Technologies, Inc. | Procede relatif a la synthese d'isoxazolidines |
KR100399361B1 (ko) * | 1999-11-04 | 2003-09-26 | 주식회사 엘지생명과학 | 캐스파제 억제제 함유 치료제 조성물 |
CN1589135A (zh) | 2001-05-30 | 2005-03-02 | 密歇根大学董事会 | Bcl-2族蛋白的小分子拮抗剂 |
FR2840807B1 (fr) | 2002-06-12 | 2005-03-11 | Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide | |
US20060020004A1 (en) * | 2004-06-17 | 2006-01-26 | Infinity Pharmaceuticals, Inc. | Isoxazolidine compounds for treatment of bacterial infections |
PT1768966E (pt) | 2004-06-17 | 2012-05-23 | Infinity Discovery Inc | Compostos e métodos para inibir a interacção de proteínas bcl com parceiros de ligação |
TWI403320B (zh) * | 2005-12-16 | 2013-08-01 | Infinity Discovery Inc | 用於抑制bcl蛋白和結合夥伴間之交互作用的化合物及方法 |
-
2006
- 2006-11-15 US US11/600,332 patent/US7842815B2/en not_active Expired - Fee Related
-
2007
- 2007-11-14 EP EP07840052.0A patent/EP2094673B1/fr active Active
- 2007-11-14 RU RU2009121808/04A patent/RU2449996C2/ru not_active IP Right Cessation
- 2007-11-14 NZ NZ577243A patent/NZ577243A/en not_active IP Right Cessation
- 2007-11-14 WO PCT/US2007/023941 patent/WO2008060569A1/fr active Application Filing
- 2007-11-14 JP JP2009537198A patent/JP2010510214A/ja active Pending
- 2007-11-14 ES ES07840052.0T patent/ES2537762T3/es active Active
- 2007-11-14 MX MX2009005184A patent/MX2009005184A/es active IP Right Grant
- 2007-11-14 CN CN200780049702.7A patent/CN101583606B/zh not_active Expired - Fee Related
- 2007-11-14 CA CA2669596A patent/CA2669596C/fr not_active Expired - Fee Related
- 2007-11-14 AU AU2007319848A patent/AU2007319848B2/en not_active Ceased
- 2007-11-14 MY MYPI20091840A patent/MY156754A/en unknown
- 2007-11-14 BR BRPI0718606-1A patent/BRPI0718606A2/pt not_active IP Right Cessation
- 2007-11-14 KR KR1020097012239A patent/KR101530721B1/ko not_active IP Right Cessation
-
2009
- 2009-05-06 IL IL198597A patent/IL198597A/en not_active IP Right Cessation
- 2009-05-08 TN TNP2009000182A patent/TN2009000182A1/fr unknown
- 2009-05-12 GT GT200900123A patent/GT200900123A/es unknown
- 2009-06-09 EC EC2009009398A patent/ECSP099398A/es unknown
- 2009-06-10 MA MA31972A patent/MA31067B1/fr unknown
- 2009-06-15 NO NO20092306A patent/NO20092306L/no not_active Application Discontinuation
- 2009-10-07 HK HK09109256.1A patent/HK1130057A1/xx not_active IP Right Cessation
-
2010
- 2010-11-30 US US12/956,969 patent/US8461191B2/en not_active Expired - Fee Related
-
2013
- 2013-11-07 JP JP2013230960A patent/JP2014055156A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US8461191B2 (en) | 2013-06-11 |
IL198597A0 (en) | 2010-02-17 |
CA2669596C (fr) | 2014-09-30 |
ECSP099398A (es) | 2009-07-31 |
AU2007319848B2 (en) | 2012-05-03 |
CN101583606A (zh) | 2009-11-18 |
IL198597A (en) | 2014-03-31 |
JP2010510214A (ja) | 2010-04-02 |
CA2669596A1 (fr) | 2008-05-22 |
ES2537762T3 (es) | 2015-06-11 |
US20080306127A9 (en) | 2008-12-11 |
RU2009121808A (ru) | 2010-12-20 |
GT200900123A (es) | 2011-09-02 |
MX2009005184A (es) | 2009-10-12 |
TN2009000182A1 (en) | 2010-10-18 |
RU2449996C2 (ru) | 2012-05-10 |
EP2094673B1 (fr) | 2015-04-08 |
US20110160259A1 (en) | 2011-06-30 |
AU2007319848A1 (en) | 2008-05-22 |
BRPI0718606A2 (pt) | 2013-12-17 |
US7842815B2 (en) | 2010-11-30 |
CN101583606B (zh) | 2015-04-08 |
WO2008060569A1 (fr) | 2008-05-22 |
JP2014055156A (ja) | 2014-03-27 |
US20070161690A1 (en) | 2007-07-12 |
KR101530721B1 (ko) | 2015-06-22 |
HK1130057A1 (en) | 2009-12-18 |
EP2094673A1 (fr) | 2009-09-02 |
MY156754A (en) | 2016-03-31 |
KR20090082284A (ko) | 2009-07-29 |
NZ577243A (en) | 2011-12-22 |
NO20092306L (no) | 2009-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31067B1 (fr) | Composés et procédés permettant d'inhiber l'interaction des protéines bcl avec des partenaires de liaison. | |
MA30673B1 (fr) | Composes et procedes d'inhibition de l'interaction de proteines bcl avec des partenaires de liaison | |
HK1105963A1 (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners | |
MA30144B1 (fr) | Composes et procedes d'inhibition de l'interaction des proteines bcl avec des partenaires de liaison | |
MA31147B1 (fr) | 4-phenyl-pyrane-3.5-diones ,4-phenyl-thiopyrane-3.5- diones et cyclohexanetriones en tant que nouveaux herbicides | |
MY151047A (en) | Iron (iii)-carbohydrate based phosphate adsorbent | |
MA31304B1 (fr) | Molecules et procedes de modulation de proproteine convertase subtilisine/kexine de type 9 (pcsk9) | |
EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
SG10201407388XA (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
MX2007004001A (es) | Metodo para el tratamiento de poliquistosis renal. | |
MA30531B1 (fr) | Anticorps anti-dll4 et leurs procedes d'utilisation | |
NO20015417D0 (no) | Behandling av autoimmune sykdommer med antagonister som binder til B-celleoverflatemarkörer | |
WO2007026251A8 (fr) | Utilisation d'inhibiteurs combines c-kit/fgfr3 pour le traitement du myelome multiple | |
MA30988B1 (fr) | Composes destines a inhiber la progression mitotique | |
TW200724140A (en) | Hydantoin compounds | |
BRPI0508084A (pt) | método para o tratamento de um distúrbio neurológico, e, uso de meridamicina ou um sal do mesmo | |
MA31526B1 (fr) | Nouveaux herbicides | |
MA31562B1 (fr) | Macrocycles et leurs utilisations | |
TNSN06418A1 (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners | |
MY155908A (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners | |
PL1819354T3 (pl) | Sposoby i związki do leczenia cukrzycy | |
TW200621265A (en) | Composition for treating tumor and/or preventing tumor transfer and recurrence | |
BG110157A (en) | INDONAL COMPOUNDS USE FOR TREATMENT OF DISABILITY OF KNOWLEDGE COMPETENCE | |
HK1144253A1 (en) | Inositol pyrophosphates determine exocytotic capacity | |
WO2006064324A3 (fr) | Hydroxyethylamines a substitution heterocycloalkyl-benzyle |